Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
Márquez-Rodas I., Longo F., Rodriguez-Ruiz ME., Calles A., Ponce S., Jove M., Rubio-Viqueira B., Perez-Gracia JL., Gómez-Rueda A., López-Tarruella S., Ponz-Sarvise M., Álvarez R., Soria-Rivas A., de Miguel E., Ramos-Medina R., Castañon E., Gajate P., Sempere-Ortega C., Jiménez-Aguilar E., Aznar MA., Calvo A., Lopez-Casas PP., Martín-Algarra S., Martín M., Tersago D., Quintero M., Melero I.
Intratumoral BO-112 combined with systemic anti–PD-1 shows immunotherapeutic potential to control tumors in patients primarily refractory to anti–PD-1.